Cite this: Intensive Statin Therapy in Coronary Artery ... MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; NSTEMI = Non-ST elevation acute myocardial infarction ...

Trials of Intensive Statin Therapy in Stable Coronary ... MIRACL = Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; NSTEMI = Non-ST elevation acute myocardial infarction ...

4, 2024 — In addition to lowering your cholesterol, keeping your brain healthy ... activity and is small enough to be packaged within a non-pathogenic virus that can deliver ...

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical ...

Additional data from BROADWAY, BROOKLYN, and TANDEM to be presented throughout 2025; expected to support global regulatory filings for obicetrapib, including EMA submission in 2H25 by our partner ...

Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ...

you may have high cholesterol even if you don’t eat foods that are rich in fat or cholesterol. Low-density lipoprotein (LDL) cholesterol is nicknamed “bad” cholesterol because it can clog ...

The cholesterol-lowering drug has been ... as well as for patients with non-inherited forms of high cholesterol who can’t meet treatment targets with a statin and PCSK9 inhibitor.

Licensed from Novartis, MAR001 is a potential first-in-class antibody. While commonly used statins are effective at lowering LDL cholesterol and triglycerides, MAR001 targets ANGPTL4, a protein highly ...

10, 2025 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam” or the "Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines ...

Other outcomes may also be relevant, for example, non-fatal cardiovascular end points. To the best of our knowledge, statins have not been systematically assessed in an ... A reference area was drawn ...